

Suggestions for thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19

Casini Alessandro^a, Alberio Lorenzo^b, Angelillo-Scherrer Anne^c, Fontana Pierre^a, Gerber Bernhard^d, Graf Lukas^e, Hegemann Inga^f, Korte Wolfgang^e, Kremer Hovinga Johanna A.^c, Lecompte Thomas^a, Martinez Maria^g, Nagler Michael^c, Studt Jan-Dirk^f, Tsakiris Dimitrios^h, Wuillemin Walterⁱ, Asmis Lars M.^j, Working Party on Hemostasis of the Swiss Society of Hematology

^a Division of Angiology and Haemostasis, University Hospitals of Geneva, Geneva, Switzerland

^b Service and Central Laboratory of Hematology, Lausanne University Hospital, Lausanne, Switzerland

^c Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

^d Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

^e Cantonal Hospital of St Gallen, St Gallen, Switzerland

^f Department of Medical Oncology and Hematology, Zurich University Hospital, Zurich, Switzerland

^g Division of Hematology, University Hospitals of Geneva, Geneva, Switzerland

^h Division of Hematology, Basel University Hospital, Basel, Switzerland

ⁱ Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne, Lucerne, Switzerland

^j Center for perioperative Thrombosis and Hemostasis, Zurich, Switzerland

Growing evidence from multiple retrospective cohorts indicates that hospitalised COVID-19 patients often could suffer from an excessive coagulation activation leading to an increased risk of venous and arterial thrombosis (including small calibre vessels) and a poor clinical course [1]. Notably, D-dimer level at the time of hospital admission is a predictor of the risk of development of acute respiratory distress syndrome (ARDS) [2], the risk of intensive care admission and the risk of death [3]. An observational study among COVID-19 patients with elevated D-dimer levels at baseline showed that the 28-day mortality was lower in those receiving heparin than in those who did not [4].

Based on the available literature and published recommendations from the International Society of Thrombosis and Hemostasis (<https://www.isth.org>), from the American Society of Hematology (<https://www.hematology.org/covid-19>) and from the Society for Thrombosis and Haemostasis Research (<http://gth-online.org>), the Working Party on Hemostasis (Swiss Society of Hematology) proposes the following recommendations for pharmacological thromboprophylaxis in COVID-19 patients in the acute setting. Suggestions will be regularly updated:

- All in-hospital COVID-19 patients should receive pharmacological thromboprophylaxis according to a risk stratification score, unless contraindicated.
- In patients with creatinine clearance >30 ml/min, low molecular weight heparin (LMWH) should be administered according to the prescribing information. An increased dose should be considered in overweight patients (>100 kg).
- In patients with creatinine clearance <30 ml/min, unfractionated heparin (UHF) subcutaneously twice or

three times daily or intravenously should be administered according to the prescribing information. An increased dose should be considered in overweight patients (>100 kg).

- Anti-Xa activity should be monitored when indicated (e.g., evidence of renal dysfunction).
- Antithrombin need not be monitored but this could be considered on an individual basis in cases of disseminated intravascular coagulation or sepsis-induced coagulopathy or heparin resistance.
- We suggest regularly monitoring prothrombin time, D-dimers, fibrinogen, the platelet count, lactate dehydrogenase (LDH), creatinine and alanine aminotransferase (ALT) (daily or at least 2–3 times per week).
- In patients in intensive care with a large increase in D-dimers, severe inflammation, or signs of hepatic or renal dysfunction or imminent respiratory failure, intermediate or therapeutic dosing of LMWH or UHF should be considered, according to the bleeding risk.
- Heparin-induced thrombocytopenia (HIT) should be considered in patients with fluctuations in platelet counts or signs of heparin resistance.
- In patients undergoing extracorporeal membrane oxygenation (ECMO) treatment we suggest maintaining UFH at doses bringing anti-Xa activity into the therapeutic range.
- There are no data on the use of direct oral anticoagulants.

Disclosure statement

No financial support and no other potential conflict of interest relevant to this article was reported.

Correspondence:

Alessandro Casini, Division of Angiology and Haemostasis, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Alessandro.Casini[at]hcuge.ch / Lars M. Asmis, Center for perioperative Thrombosis and Hemostasis, Seefeldstrasse 224, CH-8008 Zurich, Lars.Asmis[at]hin.ch

References

- 1 Tang N Li D Wang X Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844–7. doi: <http://dx.doi.org/10.1111/jth.14768>. PubMed.
- 2 Wu C Chen X Cai Y Xia J Zhou X Xu S Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020. doi: <http://dx.doi.org/10.1001/jamainternmed.2020.0994>. PubMed.
- 3 Huang C Wang Y Li X Ren L Zhao J Hu Y Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506. doi: [http://dx.doi.org/10.1016/S0140-6736\(20\)30183-5](http://dx.doi.org/10.1016/S0140-6736(20)30183-5). PubMed.
- 4 Zhou F Yu T Du R Fan G Liu Y Liu Z Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–62. doi: [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3). PubMed.